The Full Wiki

More info on Alpha-7 nicotinic receptor

Alpha-7 nicotinic receptor: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Molecular model of the alpha7 nicotinic receptor.

The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of nicotinic acetylcholine receptor, consisting entirely of α7 subunits.[1]. As with other nicotinic acetylcholine receptors, functional α7 receptors are pentameric [i.e., (α7)5 stoichiometry].

It is located in the brain, where activation yields post- and presynaptic excitation[1], mainly by increased Ca2+ permeability.






At least two types of positive allosteric modulators (PAMs) can be distinguished.[9]

  • PNU-120,596 [10]
  • NS-1738: marginal effects on α7 desensitization kinetics; modestly brain-penetrant[11]
  • XY4083: unlike the above PAMs, XY4083 does not affect α7 desensitization kinetics, and is readily brain penetrant. Improves cognitive behavior in animal models[12]
  • A-867744 [13][14]


  • α-conotoxin ArIB[V11L,V16D]: potent and highly subtype-selective; slowly reversible[15]
  • Quinolizidine (–)-1-epi-207I: α7 subtype preferring blocker[16]

See also


  1. ^ a b Pharmacology, (Rang, Dale, Ritter & Moore, ISBN 0443071454, 5:th ed., Churchill Livingstone 2003) Page 138.
  2. ^ Mazurov A, Klucik J, Miao L, et al. (2005). "2-(Arylmethyl)-3-substituted quinuclidines as selective alpha 7 nicotinic receptor ligands". Bioorg. Med. Chem. Lett. 15 (8): 2073–7. doi:10.1016/j.bmcl.2005.02.045. PMID 15808471. 
  3. ^ Tietje KR, Anderson DJ, Bitner RS, et al. (2008). "Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties". CNS Neurosci Ther 14 (1): 65–82. doi:10.1111/j.1527-3458.2008.00037.x. PMID 18482100. 
  4. ^ Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". J. Pharmacol. Exp. Ther. 309 (1): 16–27. doi:10.1124/jpet.103.061655. PMID 14722323. 
  5. ^ Acker BA, Jacobsen EJ, Rogers BN, et al. (2008). "Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl] furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity". Bioorg. Med. Chem. Lett. 18 (12): 3611–5. doi:10.1016/j.bmcl.2008.04.070. PMID 18490160. 
  6. ^ Walker DP, Wishka DG, Piotrowski DW, et al. (2006). "Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists". Bioorg. Med. Chem. 14 (24): 8219–48. doi:10.1016/j.bmc.2006.09.019. PMID 17011782. 
  7. ^ Biton B, Bergis OE, Galli F, et al. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology 32 (1): 1–16. doi:10.1038/sj.npp.1301189. PMID 17019409. 
  8. ^ Macor JE, Gurley D, Lanthorn T, et al. (2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorg. Med. Chem. Lett. 11 (3): 319–21. doi:10.1016/S0960-894X(00)00670-3. PMID 11212100. 
  9. ^ Grønlien JH, Håkerud M, Ween H, et al. (2007). "Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes". Mol. Pharmacol. 72 (3): 715–24. doi:10.1124/mol.107.035410. PMID 17565004. 
  10. ^ Hurst RS, Hajós M, Raggenbass M, et al. (2005). "A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization". J. Neurosci. 25 (17): 4396–405. doi:10.1523/JNEUROSCI.5269-04.2005. PMID 15858066. 
  11. ^ Timmermann DB, Grønlien JH, Kohlhaas KL, et al. (2007). "An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo". J. Pharmacol. Exp. Ther. 323 (1): 294–307. doi:10.1124/jpet.107.120436. PMID 17625074. 
  12. ^ Ng, HJ, et al. (2007). "Nootropic α7 nicotinic receptor allosteric modulator derived from GABA A receptor modulators". PNAS 104 (19): 8059–8064. doi:10.1073/pnas.0701321104. 
  13. ^ Faghih R, Gopalakrishnan SM, Gronlien JH, et al. (May 2009). "Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor". J. Med. Chem. 52 (10): 3377–84. doi:10.1021/jm9003818. PMID 19419141. 
  14. ^ Malysz J, Gronlien JH, Anderson DJ, et al. (April 2009). "In vitro pharmacological characterization of a novel allosteric modulator of {alpha}7 nAChR, A-867744, exhibiting unique pharmacological profile". J. Pharmacol. Exp. Ther.. doi:10.1124/jpet.109.151886. PMID 19389923. 
  15. ^ Whiteaker P, Christensen S, Yoshikami D, et al. (2007). "Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist". Biochemistry 46 (22): 6628–38. doi:10.1021/bi7004202. PMID 17497892. 
  16. ^ Tsuneki H, You Y, Toyooka N, et al. (2004). "Alkaloids indolizidine 235B', quinolizidine 1-epi-207I, and the tricyclic 205B are potent and selective noncompetitive inhibitors of nicotinic acetylcholine receptors". Mol. Pharmacol. 66 (4): 1061–9. doi:10.1124/mol.104.000729. PMID 15258256. 


Got something to say? Make a comment.
Your name
Your email address